Alumni

Main navigation

ECHO-Autism: The Diagnostic Process

Thursday, August 21, 2025 12:15to13:45

ECHO-Autism: The Diagnostic Process...

Read more about ECHO-Autism: The Diagnostic Process

ECHO-Autism: Differential Diagnosis

Thursday, September 11, 2025 13:00to14:30

ECHO-Autism: Differential Diagnosis...

Read more about ECHO-Autism: Differential Diagnosis

Human instruction with artificial intelligence guidance provided best results in neurosurgical training

Published: 6 August 2025

Study has implications beyond medical education, suggesting other fields could benefit from AI-enhanced training...

Read more about Human instruction with artificial intelligence guidance provided best results in neurosurgical training

Neuro Epilepsy Lecture Series: AI in Epilepsy: From Diagnosis to Continuous Monitoring

Thursday, September 25, 2025 16:00to17:00

The 2024-2025 Neuro Epilepsy Lecture Series will include eight lectures covering hot topics in basic and clinical epilepsy research./neuroCategory:聽Medicine and Health Sciences MNI

Read more about Neuro Epilepsy Lecture Series: AI in Epilepsy: From Diagnosis to Continuous Monitoring

Project to create AI model for ALS receives G茅nome Qu茅bec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

Read more about Project to create AI model for ALS receives G茅nome Qu茅bec funding

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Read more about Genetic sequencing project receives more than $8 million in funding

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on Parkinson鈥檚, glioblastoma and dementia 聽

Read more about Six principal investigators from The Neuro receive CIHR grants

Latest Alzheimer鈥檚 drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...